ATE549031T1 - Impfstoffzusammensetzung zur prävention von cmv- infektionen - Google Patents
Impfstoffzusammensetzung zur prävention von cmv- infektionenInfo
- Publication number
- ATE549031T1 ATE549031T1 AT08804566T AT08804566T ATE549031T1 AT E549031 T1 ATE549031 T1 AT E549031T1 AT 08804566 T AT08804566 T AT 08804566T AT 08804566 T AT08804566 T AT 08804566T AT E549031 T1 ATE549031 T1 AT E549031T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccine composition
- hcmv
- preventing
- cmv infections
- preventing cmv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97423107P | 2007-09-21 | 2007-09-21 | |
PCT/EP2008/062640 WO2009037359A1 (en) | 2007-09-21 | 2008-09-22 | Vaccine composition for the prevention of cmv infections |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE549031T1 true ATE549031T1 (de) | 2012-03-15 |
Family
ID=40029466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT08804566T ATE549031T1 (de) | 2007-09-21 | 2008-09-22 | Impfstoffzusammensetzung zur prävention von cmv- infektionen |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090104227A1 (de) |
EP (1) | EP2203184B1 (de) |
AT (1) | ATE549031T1 (de) |
CA (1) | CA2699756A1 (de) |
WO (1) | WO2009037359A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2627352B1 (de) * | 2010-10-15 | 2017-05-10 | GlaxoSmithKline Biologicals S.A. | Cytomegalovirus gb antigen |
WO2013054199A2 (en) * | 2011-10-12 | 2013-04-18 | Novartis Ag | Cmv antigens and uses thereof |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11524069B2 (en) | 2017-09-13 | 2022-12-13 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
CA3199937A1 (en) | 2020-10-28 | 2022-05-05 | Sanofi Pasteur | Liposomes containing tlr4 agonist, preparation and uses thereof |
CN113842455B (zh) * | 2021-08-27 | 2022-05-13 | 北京康乐卫士生物技术股份有限公司 | 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100064A (en) * | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
JP2009529576A (ja) * | 2006-03-10 | 2009-08-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 持続感染または潜伏感染を引き起こすウイルスに対するワクチン |
-
2008
- 2008-09-22 WO PCT/EP2008/062640 patent/WO2009037359A1/en active Application Filing
- 2008-09-22 AT AT08804566T patent/ATE549031T1/de active
- 2008-09-22 US US12/235,033 patent/US20090104227A1/en not_active Abandoned
- 2008-09-22 CA CA2699756A patent/CA2699756A1/en active Pending
- 2008-09-22 EP EP08804566A patent/EP2203184B1/de not_active Revoked
Also Published As
Publication number | Publication date |
---|---|
US20090104227A1 (en) | 2009-04-23 |
WO2009037359A1 (en) | 2009-03-26 |
EP2203184A1 (de) | 2010-07-07 |
CA2699756A1 (en) | 2009-03-26 |
EP2203184B1 (de) | 2012-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE549031T1 (de) | Impfstoffzusammensetzung zur prävention von cmv- infektionen | |
CY1117673T1 (el) | Ανασυνδυασμενα αντιγονα rsv | |
MA33806B1 (fr) | Inhibiteurs du virus de l'hepatite c | |
DE602007013618D1 (de) | Antikörper gegen das humane cytomegalie-virus (hcmv) | |
CL2013003360A1 (es) | “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct | |
EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
CR20110091A (es) | Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos | |
EA201600305A1 (ru) | Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы | |
GEP20217260B (en) | Antibody neutralizing human respiratory syncytial virus | |
EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
EA201071087A1 (ru) | Моноклональные антитела, способные взаимодействовать с множеством подтипов вируса гриппа а | |
UY34701A (es) | Formas sólidas de un profármaco de nucleótidos de tiofosforamidato | |
EA201070794A1 (ru) | Рекомбинантные антигены rsv | |
EA029939B8 (ru) | Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение | |
WO2008039267A3 (en) | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions | |
BR112014004860A2 (pt) | composições de anticorpo contra vírus da influenza | |
ME01140B (me) | Virus goveđe virusne dijareje s modifikovanim erns proteinom | |
UA101814C2 (ru) | Фактор, задействованный в латентной инфекции герпесвирусом, и его применение | |
WO2013106689A8 (en) | Hcv ns3 protease inhibitors | |
EA201300132A1 (ru) | Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич | |
CL2009001195A1 (es) | Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune. | |
MX2013004906A (es) | Nuevos inhibidores especificos de la proteasa ns3 de hcv. | |
CL2011003002A1 (es) | Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento. | |
BRPI0910884A2 (pt) | composição imunogênica, método para tratar ou prevenir infecção ou doença estafilocócicas, e, uso de uma composição imunogênica. | |
EP2224943A4 (de) | Verwendung eines humanen antikörpers zur neutralisierung von hepatitis-b-virus zur prävention oder behandlung von hepatitis-b-infektionen |